209 related articles for article (PubMed ID: 19426159)
1. CXCL16 and oxLDL are induced in the onset of diabetic nephropathy.
Gutwein P; Abdel-Bakky MS; Doberstein K; Schramme A; Beckmann J; Schaefer L; Amann K; Doller A; Kämpfer-Kolb N; Abdel-Aziz AA; El Sayed el SM; Pfeilschifter J
J Cell Mol Med; 2009 Sep; 13(9B):3809-25. PubMed ID: 19426159
[TBL] [Abstract][Full Text] [Related]
2. CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein.
Gutwein P; Abdel-Bakky MS; Schramme A; Doberstein K; Kämpfer-Kolb N; Amann K; Hauser IA; Obermüller N; Bartel C; Abdel-Aziz AA; El Sayed el SM; Pfeilschifter J
Am J Pathol; 2009 Jun; 174(6):2061-72. PubMed ID: 19435795
[TBL] [Abstract][Full Text] [Related]
3. oxLDL-induced lipid accumulation in glomerular podocytes: role of IFN-γ, CXCL16, and ADAM10.
Wang L; Sun S; Zhou A; Yao X; Wang Y
Cell Biochem Biophys; 2014 Sep; 70(1):529-38. PubMed ID: 24752304
[TBL] [Abstract][Full Text] [Related]
4. Atherogenic lipids induce high-density lipoprotein uptake and cholesterol efflux in human macrophages by up-regulating transmembrane chemokine CXCL16 without engaging CXCL16-dependent cell adhesion.
Barlic J; Zhu W; Murphy PM
J Immunol; 2009 Jun; 182(12):7928-36. PubMed ID: 19494317
[TBL] [Abstract][Full Text] [Related]
5. Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney.
Schramme A; Abdel-Bakky MS; Gutwein P; Obermüller N; Baer PC; Hauser IA; Ludwig A; Gauer S; Schäfer L; Sobkowiak E; Altevogt P; Koziolek M; Kiss E; Gröne HJ; Tikkanen R; Goren I; Radeke H; Pfeilschifter J
Kidney Int; 2008 Aug; 74(3):328-38. PubMed ID: 18480749
[TBL] [Abstract][Full Text] [Related]
6. oxLDL promotes podocyte migration by regulating CXCL16, ADAM10 and ACTN4.
Chen Y; Wang Z; Li Q; Yu L; Zhu Y; Wang J; Sun S
Mol Med Rep; 2020 Sep; 22(3):1976-1984. PubMed ID: 32705248
[TBL] [Abstract][Full Text] [Related]
7. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16.
Gough PJ; Garton KJ; Wille PT; Rychlewski M; Dempsey PJ; Raines EW
J Immunol; 2004 Mar; 172(6):3678-85. PubMed ID: 15004171
[TBL] [Abstract][Full Text] [Related]
8. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.
Gutwein P; Schramme A; Sinke N; Abdel-Bakky MS; Voss B; Obermüller N; Doberstein K; Koziolek M; Fritzsche F; Johannsen M; Jung K; Schaider H; Altevogt P; Ludwig A; Pfeilschifter J; Kristiansen G
Eur J Cancer; 2009 Feb; 45(3):478-89. PubMed ID: 19070478
[TBL] [Abstract][Full Text] [Related]
9. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10.
Abel S; Hundhausen C; Mentlein R; Schulte A; Berkhout TA; Broadway N; Hartmann D; Sedlacek R; Dietrich S; Muetze B; Schuster B; Kallen KJ; Saftig P; Rose-John S; Ludwig A
J Immunol; 2004 May; 172(10):6362-72. PubMed ID: 15128827
[TBL] [Abstract][Full Text] [Related]
10. The role of CXCL16 and its processing metalloproteinases ADAM10 and ADAM17 in the proliferation and migration of human mesangial cells.
Schramme A; Abdel-Bakky MS; Kämpfer-Kolb N; Pfeilschifter J; Gutwein P
Biochem Biophys Res Commun; 2008 May; 370(2):311-6. PubMed ID: 18373975
[TBL] [Abstract][Full Text] [Related]
11. Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha- and gamma-secretases.
Schulte A; Schulz B; Andrzejewski MG; Hundhausen C; Mletzko S; Achilles J; Reiss K; Paliga K; Weber C; John SR; Ludwig A
Biochem Biophys Res Commun; 2007 Jun; 358(1):233-40. PubMed ID: 17467666
[TBL] [Abstract][Full Text] [Related]
12. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes.
Hundhausen C; Schulte A; Schulz B; Andrzejewski MG; Schwarz N; von Hundelshausen P; Winter U; Paliga K; Reiss K; Saftig P; Weber C; Ludwig A
J Immunol; 2007 Jun; 178(12):8064-72. PubMed ID: 17548644
[TBL] [Abstract][Full Text] [Related]
13. Constitutive expression and regulated release of the transmembrane chemokine CXCL16 in human and murine skin.
Scholz F; Schulte A; Adamski F; Hundhausen C; Mittag J; Schwarz A; Kruse ML; Proksch E; Ludwig A
J Invest Dermatol; 2007 Jun; 127(6):1444-55. PubMed ID: 17363916
[TBL] [Abstract][Full Text] [Related]
14. Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury.
Okamura DM; López-Guisa JM; Koelsch K; Collins S; Eddy AA
Am J Physiol Renal Physiol; 2007 Aug; 293(2):F575-85. PubMed ID: 17537985
[TBL] [Abstract][Full Text] [Related]
15. Enoxaparin prevents CXCL16/ADAM10-mediated cisplatin renal toxicity: Role of the coagulation system and the transcriptional factor NF-κB.
Aboyoussef AM; Abdel-Sattar AR; Abdel-Bakky MS; Messiha BAS
Life Sci; 2021 Apr; 270():119120. PubMed ID: 33545204
[TBL] [Abstract][Full Text] [Related]
16. Activation of the CXCL16/CXCR6 Pathway by Inflammation Contributes to Atherosclerosis in Patients with End-stage Renal Disease.
Hu ZB; Chen Y; Gong YX; Gao M; Zhang Y; Wang GH; Tang RN; Liu H; Liu BC; Ma KL
Int J Med Sci; 2016; 13(11):858-867. PubMed ID: 27877078
[No Abstract] [Full Text] [Related]
17. TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation.
Izquierdo MC; Sanz AB; Mezzano S; Blanco J; Carrasco S; Sanchez-Niño MD; Benito-Martín A; Ruiz-Ortega M; Egido J; Ortiz A
Kidney Int; 2012 Jun; 81(11):1098-107. PubMed ID: 22278019
[TBL] [Abstract][Full Text] [Related]
18. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis.
Aslanian AM; Charo IF
Circulation; 2006 Aug; 114(6):583-90. PubMed ID: 16880330
[TBL] [Abstract][Full Text] [Related]
19. Human P2X7 receptor activation induces the rapid shedding of CXCL16.
Pupovac A; Foster CM; Sluyter R
Biochem Biophys Res Commun; 2013 Mar; 432(4):626-31. PubMed ID: 23428418
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity.
Gooden MJ; Wiersma VR; Boerma A; Leffers N; Boezen HM; ten Hoor KA; Hollema H; Walenkamp AM; Daemen T; Nijman HW; Bremer E
Br J Cancer; 2014 Mar; 110(6):1535-44. PubMed ID: 24518602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
